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Background: Epithelial-to-mesenchymal transition (EMT) is a key step of the progression of tumor cell metastasis.
Recent work has demonstrated some miRNAs play critical roles in EMT. In this study, we focused on the roles of
miR-300 in regulating EMT.
Methods: The expression levels of miR-300 were examined in epithelial carcinoma cells that underwent an EMT
using quantitative reverse transcription-PCR. The role of miR-300 in EMT was investigated by transfection of the
miR-300 mimic or inhibitor in natural epithelial-mesenchymal phenotype cell line pairs and in transforming growth
factor (TGF) beta-induced EMT cell models. A luciferase reporter assay and a rescue experiment were conducted to
confirm the target gene of miR-300. The efficacy of miR-300 against tumor invasion and metastasis was evaluated
both in vitro and in vivo. Correlation analysis between miR-300 expression and the expression levels of its target
gene, as well as tumor metastasis was performed in specimens from patients with head and neck squamous cell
carcinoma (HNSCC).
Results: MiR-300 was found down-regulated in the HNSCC cells and breast cancer cells that underwent EMT.
Ectopic expression of miR-300 effectively blocked TGF-beta-induced EMT and reversed the phenotype of EMT in
HN-12 and MDA-MB-231 cells, but inhibition of miR-300 in the epithelial phenotype cells, HN-4 and MCF-7 cells,
could induce EMT. The luciferase reporter assay and the rescue assay results showed that miR-300 directly targets
the 3′UTR of Twist. Enforced miR-300 expression suppressed cell invasion in vitro and experimental metastasis
in vivo. Clinically, miR-300 expression was found inversely correlated with Twist expression and reduced miR-300
was associated with metastasis in patient specimens.
Conclusions: Down-regulation of miR-300 is required for EMT initiation and maintenance. MiR-300 may negatively
regulate EMT by direct targeting Twist and therefore inhibit cancer cell invasion and metastasis, which implicates
miR-300 as an attractive candidate for cancer therapy.
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MicroRNAs (miRNAs) are evolutionarily conserved, 20–
22 nucleotide noncoding RNAs. They exert their func-
tion by binding to the 3′-untranslated region (3′UTR) of
a subset of mRNAs resulting in reduced translation of
proteins or degradation of the mRNAs [1]. The import-
ance of miRNAs in tumor development and progression* Correspondence: chenwantao2002@hotmail.com; xuqin_2004@hotmail.com
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unless otherwise stated.has become increasingly evident [2]. Some miRNAs have
been shown to exert diverse functions in cancer cell pro-
liferation, angiogenesis and epithelial-to-mesenchymal
transition (EMT) [3,4].
EMT is a complex trans-differentiation process in which
epithelial cells lose junctional adhesion and adopt a mes-
enchymal phenotype and morphology. During the EMT
process, epithelial cells can migrate through the extracel-
lular matrix. In cancer, EMT allows neoplasic cells to be-
come motile and invasive, and leave the primary epithelialThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tial of carcinomas [5,6].
Transforming growth factor-β (TGF-β) was first de-
scribed as an inducer of EMT in normal mammary epi-
thelial cells and has since been shown to mediate EMT
in vitro in most epithelial cells [7,8]. The process of
EMT is also regulated by several transcription factors, in-
cluding Twist (also known as Twist1), SNAIL, SLUG, ZEB1
and ZEB2, as reviewed in [9], which are transcriptional
repressors of E-cadherin. Recent work has demon-
strated some miRNAs play critical roles in EMT. Mem-
bers of the miR-200 family are well-established EMT
repressors through direct targeting of ZEB1 and ZEB2
[10,11]. However, reports of the roles of other miRNAs
in the regulation of EMT are limited.
Recently, using miRNA microarray analysis, we identi-
fied a group of differentially expressed miRNAs between
mesenchymal-like cancer cells and epithelial-like cancer
cells [12]. Remarkably, miR-300 was down-regulated in
cancer cells that have undergone EMT comparing with
typical epithelial phenotype carcinoma cells, indicating
miR-300 might be a regulator of EMT. Based on this
finding, miR-300 was chosen for further investigation.
In this study, we verified that miR-300 was down-
regulated during an EMT. The low expression of miR-
300 plays an important role in EMT-mediated tumor
metastasis. Furthermore, we show that Twist is a direct
target of miR-300. Ectopic expression of miR-300 could
repress invasion in vitro and experimental pulmonary
metastases in vivo. In addition, the expression level of
miR-300 is associated with metastatic pattern in oral
squamous cell carcinoma.
Results
Down-regulation of miR-300 in cells having undergone EMT
The weakly invasive head and neck squamous cell car-
cinoma (HNSCC) cell line HN-4 and human breast can-
cer cell line MCF-7 exhibited a characteristic epithelial
cobblestone-like morphology with high expression of the
epithelial marker E-cadherin and low expression of the
mesenchymal marker Vimentin. In contrast, the highly
invasive HNSCC cell line HN-12 and breast cancer cell line
MDA-MB-231 were of more elongated, fibroblast-like
mesenchymal appearance with reduced E-cadherin and
increased Vimentin expression. In addition, HN-4 and
MCF-7 cells treated with TGF-β lost their epithelial
morphology and acquired mesenchymal traits (Figure 1A,B).
These results indicate that the HN-4 and MCF-7 cells
are typical epithelial phenotype carcinoma cells, whereas
HN-12 and MDA-MB-231 cells have undergone an
EMT. Moreover, TGF-β can induce an EMT process in
HN-4 and MCF-7 cells. Previously, by miRNA array ana-
lysis, we identified a group of differentially expressed miR-
NAs between epithelial-like cancer cells (HN-4 cells) andmesenchymal-like cancer cells (HN-12 cells and TGF-β
induced HN-4 cells) [12]. Expression array data are avail-
able at GEO datasets (#GSE38459). In the present study,
real-time PCR verification was performed to verify the
miRNA array results, which confirmed 15 down-regulated
miRNAs in the cells that underwent EMT (Figure 1C).
Some of these miRNAs, such as miR-200a and miR-200c,
two miR-200 family miRNAs, have been previously dem-
onstrated as EMT negative regulators [13]. In addition to
miR-200 family, miR-300 was one of the most down-
regulated miRNAs in both HNSCC cells and breast cancer
cells that underwent EMT (Figure 1C,D). So far, no direct
evidence has been reported that miR-300 may affect EMT,
therefore, we selected miR-300 for further analysis as an
unknown candidate regulator of EMT.
Overexpression of miR-300 blocks TGF-β induced EMT
Overexpression of miR-300 led to significant resistance
to TGF-β induced EMT (Figure 2). The cobblestone-like
appearance and E-cadherin expression remained intact and
Vimentin expression was attenuated in the cells treated
with TGF-β in combination with miR-300. These data sug-
gest that miR-300 is necessary for TGF-β-induced EMT.
Overexpression of miR-300 reverses the mesenchymal
characteristics of HN-12 and MDA-MB-231 cells
Next, we tested the ability of miR-300 to reverse the
mesenchymal phenotype of highly invasive cancer cells,
HN-12 and MDA-MB-231. Firstly, stable cell lines of
HN-12 and MDA-MB-231cells with ectopic expression
of miR-300 were generated by transfection of miR-300
precursor. Comparing with their parental cells, HN-12
and MDA-MB-231 cells ectopically expressing miR-300
showed an obvious shift in morphology, from spindle-
shaped cells to more cobblestone-like cells (Figure 3A).
Western Blot analysis revealed a significant increase of
E-cadherin expression and reduced Vimentin expression
in miR-300 overexpression cells (Figure 3B). Significant
decrease of in vitro invasive abilities was also observed
in these cells (Figure 3C). These results indicate that
miR-300 is required for EMT maintenance in mesenchymal
phenotype cells.
Reducing miR-300 level induces EMT in HN-4 and
MCF-7 cells
As a consequence of stable knockdown of miR-300, HN-
4 and MCF-7 cells showed cellular changes consistent
with EMT and increased invasiveness. HN-4 and MCF-7
cells with down-regulated level of miR-300 acquired a
fibroblastoid appearance (Figure 3D). Western blot con-
firmed a strong reduction of E-cadherin expression
and a concomitant induction of Vimentin in these cells
(Figure 3E). In addition, downregulation of miR-300 led
to increased cell invasion (Figure 3F). These results show
Figure 1 (See legend on next page.)
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Figure 1 Down-regulation of miR-300 in cells having undergone EMT. A.,B. Morphology, E-cadherin and Vimentin expression levels and
invasive behavior analysis of HN-4 cells, HN-12 cells and TGF-β-treated HN-4 cells (A) or MCF-7 cells, MDA-MB-231 cells and TGF-β-treated MCF-7
cells (B). Left panel showed the phase contrast microscopy and immunofluorescence staining of E-cadherin and Vimentin in the indicated cells.
Right-upper panel showed the invasive behavior of the indicated cells in transwell assays. Right-lower panel showed the Western blot analysis of
E-cadherin and Vimentin protein levels in the indicated cells. C. Fifteen miRNAs, including miR-300, were confirmed down-regulated in the HNSCC cells
that underwent EMT by real-time PCR. D. The down-regulation of miR-300 was also observed in breast cancer cells that underwent EMT. * P < 0.05.
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ciently induce EMT.
Twist is a direct target of miR-300
Based on the miR- target analysis using TargetScan web-
site (www.targetscan.org), Twist was predicted as a po-
tential target gene of miR-300. The predicted binding of
miR-300 with Twist 3′UTR was illustrated (Figure 4A).
To examine whether miR-300 directly interacts with the
predicted 3′UTR of Twist, the 3′UTR of human Twist
was cloned downstream the firefly luciferase coding se-
quence and co-transfected with miR-300 mimic into
293 T cells. Indeed, normalized firefly luciferase activity
decreased by 64% compared with the transfected control.
In addition, site-directed mutagenesis of the seed regionFigure 2 Overexpression of miR-300 blocks TGF-β induced EMT. A. Ph
cells treated with TGF-β alone and co-incubated with miR-300 mimic. B. W
following the mentioned treatments. C. Western blot analysis of E-cadheri
mentioned treatments.abolished the inhibitory effect of miR-300 on firefly lucif-
erase activity (Figure 4B). To demonstrate that the en-
dogenous miR-300 can regulate the expression of Twist,
the miR-300 inhibitor was transfected into HN-4 and
MCF-7 cells. As shown in Figure 4C, the miR-300 inhibitor
increased the normalized firefly luciferase activity, as com-
pared to the negative control (NC) (Figure 4C). Twist pro-
tein expression decreased when HN-12 and MDA-MB-231
cells were treated with miR-300 mimic and increased when
HN-4 and MCF-7 cells were treated with miR-300 inhibitor
(Figure 4D,E). To ascertain that the miR-300 regulates
EMT through its interaction with Twist, a rescue experi-
ment was also performed. Overexpression of Twist rescued
the repressive effects of miR-300 on EMT, leading to mor-
phological and molecular changes consistent with EMTase contrast microscopy of HN-4 (upper panel) and MCF-7 (lower panel)
estern blot analysis of E-cadherin and Vimentin staining in HN-4 cells
n and Vimentin staining in MCF-7 cells following the
Figure 3 (See legend on next page.)
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Figure 3 Down-regulation of miR-300 is required for EMT initiation and maintenance. A. Ectopic expression of miR-300 produced obvious
morphological changes in HN-12 and MDA-MB-231, from spindle-shaped cells to more cobblestone-like cells. B. Western Blot analysis revealed a
significant increase of E-cadherin expression and reduced Vimentin expression in miR-300 overexpression cells. C. Significant decrease of in vitro
invasive abilities of cells was observed in cells with ectopic expression of miR-300 in transwell assays. D. HN-4 and MCF-7 cells with down-regulated
level of miR-300 acquired a fibroblastoid appearance. E. Western blot confirmed a strong reduction of E-cadherin expression and a concomitant
induction of Vimentin in these cells. F. Downregulation of miR-300 led to increased cell invasion in transwell assays. * P < 0.05.
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(Figure 4I). These data indicate that miR-300 targets Twist,
which in turn results in a negative regulation of EMT.miR-300 inhibits the experimental lung metastasis in vivo
EMT is a key step of the progression of tumor cell me-
tastasis. Therefore, EMT inhibition may be a way to
suppress cancer metastasis [14]. For this purpose, we
next investigated whether miR-300 could inhibit the
experimental lung metastasis in vivo. The lung metas-
tasis models were established by the tail vein injection
of MDA-MB-231 cells transfected with a blank vector
and MDA-MB-231cells over-expression of miR-300.
The metastatic nodules were counted on the surface of
lung after 6 weeks and confirmed by histological exam-
ination (Figure 5B). As shown in Figure 5A,C,D, the
tumor nodules and total lung weight were dramatically
reduced in miR-300 over-expression group. The lung
weight and the tumor nodules of mice in miR-300
over-expression group were respectively 40% and 66%
less than that in negative control group, which indi-
cates miR-300 can inhibit tumor metastasis in vivo. Ex-
pression of Twist was analyzed by Western blot in lung
homogenates from four randomly selected animals in
both groups. The expression of Twist was significantly
depressed in the miR-300 treated animals compared to
negative controls.miR-300 expression is inversely correlated with Twist
expression and metastasis in tumors from patients with
oral cancer
To address whether the expression of miR-300 is associated
with its target, Twist in patients, miR-300 and Twist ex-
pression were examined in specimens from 75 patients with
oral cancer. It was shown that a significant inverse correl-
ation between Twist and miR-300 expression levels by
Pearson correlation analysis (R = −0.367, P = 0.001) in these
patients (Figure 6A). These data provide further evidence of
a functional link between miR-300 and Twist in cancer
patients. In addition, the miR-300 expression level in
metastasis-positive patients (n = 35) was significantly lower
(P =0.033) than that in metastasis-negative patients (n = 40)
(Figure 6B). Conversely, Twist was expressed at higher
levels in patients with metastasis than those without metas-
tasis (P =0.041) (Figure 6C).Discussion
Metastasis is the primary cause of mortality in most can-
cer patients [15]. Thus, to understand the molecular
mechanisms of metastasis is one of the most important
issues in cancer research. Epithelial-mesenchymal transi-
tion (EMT), which enables epithelial cells to acquire in-
vasive mesenchymal phenotype, is attracting increasing
attention as an important mechanism for the initial step
of metastasis [16,17]. Recently, several miRNAs, such as
the miR-200 family, have appeared as powerful master
regulators of EMT. In this study, we observed that miR-
300, a miRNA with so far unknown function in metasta-
sis, played an important role as a suppressor of EMT in
human epithelial cancer through direct targeting Twist,
which, in turn, inhibited metastasis.
Previously, we identified a group of differentially
expressed miRNAs between mesenchymal-like and
epithelial-like cancer cells [12]. In this study, these dys-
regulated miRNAs were verified by real-time PCR in
two types of cancer cells, breast cancer cells and oral
cancer cells. It was observed that miR-300 was signifi-
cantly down-regulated both in natural mesenchymal
phenotype cells (HN-12 cell and MDA-MB-231 cell) and
EMT cell culture models by exposure to TGF-β com-
pared with epithelial phenotype cells (HN-4 cell and
MCF-7 cell). These results imply that miR-300 may
function as an EMT regulator.
Furthermore, our data demonstrated that over-expression
of miR-300 in cancer cells could prevent TGF-β-induced
EMT. In addition, the ectopic expression of miR-300 is
sufficient to reverse the mesenchymal characteristics
and decrease the invasive abilities of mesenchymal
phenotype cells. In contrast, by inhibition of miR-300,
epithelial phenotype cells could be triggered to undergo
EMT, which was accompanied by a more invasive prop-
erty. Our findings showed that down-regulation of miR-
300 is required for EMT initiation and maintenance.
More importantly, the involvement of miR-300 in the
regulation of EMT was observed in two different types
of cancer, breast cancer and oral cancer, suggesting it is
a common regulatory mechanism of tumor cell invasion
rather than a tissue-specific one.Identifying targets is
critical for understanding the biological effects of
miRNA [18]. In the present study, Twist was predicted
as the target of miR-300 by TargetScan. This interaction
between miR-300 and Twist mRNA has not been
Figure 4 Twist is a direct target of miR-300. A. The predicted binding of miR-300 with Twist 3′UTR was illustrated. B. A dual-luciferase reporter
system analysis was performed to validate miR-300 target genes. A 3′UTR fragment containing the predicted miR-300 targeting sites of Twist
was fused downstream of the firefly luciferase gene. A miR-300 mutated binding site (mut) was also constructed. Cotransfection of Twist 3′UTR
with miR-300 mimic led to a strong reduction of the luciferase signal. Mutagenesis of the seed region resulted in a reversal of this inhibition.
C. Endogenous study showed that cotransfection of Twist 3′UTR with miR-300 inhibitor caused an elevated luciferase signal in both HN-4 and MCF-7
cells. D, E. Western blot analysis of Twist protein expression in HN-12 and MDA-MB-231 cells treated with miR-153 mimic (D) or in HN-4 and MCF-7
cells treated with miR-153 inhibitor F, G, H, I. Overexpression of Twist rescued the repressive effects of miR-300 on EMT, leading to morphological
changes (F), molecular changes consistent with EMT (G, H), and elevated invasive abilities in transwell assays (I). * P < 0.05.
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Figure 5 miR-300 inhibits the experimental lung metastasis in vivo. A. Images of lungs from all mice intravenously injected with MDA-MB-
231 cells and with MDA-MB-231cells over-expression of miR-300 (n = 7). B. The histological examination of metastatic nodules. C. The mean lung
weights of the different experimental groups. D. The number of tumor nodules on the lung surface of the different experimental groups. E. Expression
of Twist was analyzed by Western blot in lung homogenates from four randomly selected animals in both groups. * P < 0.05.
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confirmed the Twist 3′UTR as a direct target of miR-
300. The role of Twist in promoting EMT processes has
been widely reported [19,20]. Elevated Twist expression
was also related with tumor invasion and metastasis inFigure 6 miR-300 expression is inversely correlated with Twist expres
cancer. A. The grey dotted line and the solid grey line indicated the medi
median was considered as “high” and “low,” respectively. Significant inverse
specimens (R = −0.367, P = 0.001). White boxes indicated cases with inverse
showed cases with no inverse relationship between miR-300 and Twist (n =
was significantly lower (P =0.033) than that in metastasis-negative patients. C.
higher (P =0.041) than that in metastasis-negative patients.several solid cancers, such as oral cancer [20], esophageal
squamous cell carcinomas [21], prostate cancer [22], and
uterine cancer [23]. Although Twist has been reported to
promote EMT and tumor metastasis through repression
of E-cadherin expression, few known miRNA regulators ofsion and metastasis in primary tumors from patients with oral
an value of miR-300 and Twist. Expression either above or below the
correlation was observed between miR-300 and Twist in patient
expression pattern of miR-300 and Twist (n = 47), while shaded boxes
28). B. The miR-300 expression level in metastasis-positive patients
The Twist expression level in metastasis-positive patients was significantly
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for the first time, we provided evidence that Twist is a
direct target of miR-300. As Twist plays an essential role
in EMT as well as tumor metastasis, our data establish a
mechanistic link between miR-300, Twist, EMT and
tumor metastasis.
Given the critical role of EMT in metastatic tumor for-
mation, inhibition of EMT can be an important thera-
peutic strategy to inhibit tumor metastasis [24,25]. As a
matter of fact, we have shown that miR-300 could de-
crease in vitro invasive behavior of highly invasive can-
cer cells, suggesting it might be a rational approach of
treatment against metastasis. Therefore, we subsequently
turned our attention to the anti-metastatic efficacy of
miR-300 in a mouse model of experimental lung metas-
tasis. In accordance with our in vitro findings, ectopic
expression of miR-300 in MDA-MB-231cells led to
approximate 2.9-fold decrease in the number of lung me-
tastasis tumor nodules compared with vector control cells,
providing in vivo evidence that miR-300 has therapeutic
potential for metastasis prevention. (HN-12 cells were also
employed for animal study, however they failed to develop
experimental metastasis model. Data not shown). In
addition, levels of Twist protein in lung lysates from miR-
300 treated mice were markedly reduced compared with
control mice, further confirming that the Twist gene is a
true target of miR-300. The miR-300 mediated inhibition
of invasion and metastasis likely operates through its sup-
pression effect on EMT.
To gain further insights into the role of miR-300 in oral
cancer metastasis, the expression of miR-300 and Twist
was detected in 75 oral cancer samples. A significant in-
verse correlation between miR-300 and Twist expression
levels was observed, which confirms the functional inter-
action of miR-300 and its target Twist. Furthermore, sig-
nificant lower levels of miR-300 and higher levels of Twist
were found in patients with metastasis than that in pa-
tients without metastasis. Although low level expression
of miR-300 was reported in some types of cancer [26-28],
the exact role of miR-300 in cancerous transformation
and progression is not clear. Our data provide evidence
that down-regulation of miR-300 is involved in metastatic
events, which is consistent with the function of miR-300
in modulating EMT. These results reveal a previously un-
known function of miR-300 to prevent metastasis by sup-
pressing EMT.
Conclusions
In summary, our study suggests that down-regulation of
miR-300 is required for EMT initiation and mainten-
ance. MiR-300 plays an important role in EMT through
direct targeting of Twist. Ectopic expression of miR-300
can reduce invasiveness and metastasis of cancer cells
both in vitro and in vivo (Figure 7).Methods
Cell culture
Two HNSCC cell lines (HN-12 and HN-4 cells) were
obtained from the National Institutes of Health (NIH).
Two human breast cancer cells (MDA-MB-231and MCF-
7 cells) were purchased from American Type Culture
Collection (ATCC). All cells were cultured in DMEM
containing 10% (v/v) FBS, 100 U/mL of penicillin, and
100 mg/mL of streptomycin at 37°C, 5% CO2 in a hu-
midified atmosphere. HN-4 cells are primary squamous
cell carcinoma cells of the tongue with low invasive ability,
while HN-12 cells were derived from a nodal metastasis in
the patient from whom the HN-4 cells originated that
have relatively high invasive ability [29]. MDA-MB-231
and MCF-7 cells are commonly used breast cancer cell
lines. MCF-7 cells have been found to exhibit low inva-
sive abilities. By contrast, MDA-MB-231 cells have a
high invasive potential [30]. Induction of EMT in epi-
thelial cancer cells was initiated by addition of 10 ng/ml
TGF-β1 (Invitrogen) to the medium for up to 72 h.
RNA preparation and quantitative real-time PCR (qRT-PCR)
Total RNA from cultured cells was extracted using Trizol
(Invitrogen). Roche’s High Pure miRNA kit was used for
total RNA extraction from formalin-fixed paraffin-
embedded (FFPE) tissue samples. For quantitative analysis
of Twist mRNAs, total RNA was treated with DNase I to
eliminate contaminating genomic DNA, and was reverse-
transcribed into cDNA with the Reverse Transcriptase
MMLV (Takara). The realtime PCR analysis was per-
formed using the SYBR® PrimeScript™ RT-PCR Kit
(Takara) on an ABI 7300 Real-Time PCR System. The
PCR condition was as follows: 95°C for 5 min, 40 cycles
of 30 sec at 95°C, 30 sec at 68°C, 60 seconds at 72°C. All
samples were normalized to GAPDH. For quantitative
analysis of miRNAs, all the miRNAs in the total RNA
samples were polyadenlyated and reverse-transcribed.
The resulting cDNA was then subjected to real-time
PCR. The entire sequences of miRNAs were used as
specific forward primers in combination with the uni-
versal reverse qPCR primer provided in the kit. Quanti-
tative Real-time PCR was used under the following
thermocycler conditions: 95°C for 30 sec, 40 cycles of
95°C for 5 sec, and 60°C for 30 sec. MiRNA values were
normalized to U6 small nuclear RNA from the same sam-
ple. The ΔCt and 2−ΔΔCt methods were used for analysis.
All the real time PCR reactions were run in triplicate. The
specific primer pairs used are listed in the Table 1.
Immunofluorescence and confocal laser scanning
microscopy
Confocal laser scanning microscopy was performed using
a Leica TCS SP2 microscope (Leica Microsystems) as pre-
viously reported [31]. Briefly, cells were grown on 10 mm
Figure 7 Schematic diagram of miR-300’s regulation of EMT and metastasis. By targeting Twist, miR-300 plays an important role in the
regulation of EMT.
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fixation for 10 min, cells were incubated with an E-
cadherin antibody (1:100, Invitrigen) or Vimentin anti-
body (1:100, Sigma), followed by incubation with goat-
anti-mouse-Alexa 594 conjugated antibodies (1:500,
Invitrogen). Cell nuclei were counterstained with DAPI
(1:1000, Invitrogen). Confocal image series were re-
corded on a LEICA TCS SP2 laser scanning microscope.
Western blot analysis
Cells and murine lung tissue specimens were homogenized
in extraction buffer (50 mM HEPES, 250 mM NaCl, 5 mM
EDTA, 0.1% NP-40, 1 mM PMSF,1 mM DTT supple-
mented with Protease inhibitor cocktail). Whole proteins
were extracted by centrifugation (12,000 × g) for 10 min at
4°C. Protein concentration was determined using the BCA
kit (Pierce). Equal amounts of protein (20 μg/lane) from
the cell lysates were electrophoresed under nonreducing
conditions on 10% acrylamide gels. After SDS-PAGE,
proteins were transferred to a polyvinylidene difluoride
membrane. The membrane was incubated for 2 h in





U6 F 5′-CGCAAGGATGACACG CAAATTCGT-3′
Twist 3′UTR F 5′-TCCCCCGGGAAGCAGCTACTGACAGGC-3′
Twist 3′UTR R 5′-CCCAAGCTTGTATGATCTCACCAGGGA-3′
Twist qPCR F 5′-GGACAAGCTGAGCAAGAT-3′
Twist qPCR R 5′-CTCTGGAGGACCTGGTAG-3′
*F, forward; R, reverse.block nonspecific binding. Subsequently, the membrane
was incubated for 2 h with an antibody against E-cadherin
(1:500, Invitrigen), Vimentin (1:500, Sigma) and Twist
(1:400, Abcam), followed by incubation with fluorescent
secondary antibodies (1:5000, IRDye 800 anti-mouse Mo-
lecular Probes, Rockland). Blots were stripped and
reprobed by using anti-actin antibody (Santa Cruz Bio-
technology). Images were acquired with the Odyssey infra-
red imaging system and analyzed by the software program
as specified by Odyssey.
Transwell invasion assay
Cell invasion was studied using Matrigel-coated trans-
well inserts as described previously [32]. Briefly, trans-
well inserts with 8 μm pores were coated with Matrigel
(50 μg/well, BD Biosciences). 200 μl of cell suspension
(1 × 106/ml) was added to the upper chambers, and
600 μl of DMEM medium containing 5% fetal bovine
serum was placed in the lower wells. Thereafter, the cells
were incubated for 24 h. Cells that had invaded to lower
surface of the Matrigel-coated membrane were fixed with
70% ethanol, stained with hematoxylin, and counted in
five random fields under a light microscope.
Transfection of miRNA mimics and inhibitors
A total of 2 × 105 cells were plated in triplicate overnight
in antibiotic-free complete medium in 6-well plates. The
cells were then transiently transfected with 200 μL con-
taining 100 nM of a mature miRNA mimic or inhibitor
using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s protocol. 72 h after transfection, the total
RNA and protein were collected for further analysis.
The sequences of miR-300 were as follows:
Sense: 5′- UAUACAAGGGCAGACUCUCUCU-3′.
Anti-sense: 5′- AGAGAGAGUCUGCCCUUGUAUA-3′.
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5′-GAGAGAGUCUGCCCUUGUAU-3′.
Generation of stable cell lines with overexpression or
knockdown of miR-300
The miR-300 precursor expression plasmid, inhibitor ex-
pression plasmid and non-targeting control plasmid were
obtained from Genechem. Cells were plated in 6-well
plates at a density of 5 × 105 cells per well, and incubated
overnight before transfection. Plasmid transfections were
performed using Lipofectamine 2000 transfection reagent
(Invitrogen) according to the manufacturer’s instructions.
After transfection, cells were grown in the presence of
Hygromycin (300 μg/ml) to generate stably transfected
cell lines.
Bioinformatic prediction of miR-300 potential targets
The data bases TargetScan (www.targetscan.org) was used
to predict potential targets for miR-300 [33].
Luciferase reporter assay
The Twist 3′ UTR segment, which contains the putative
binding site for miR-300 was amplified by PCR from HN-
12 cells genomic DNA and inserted into the SmaI and
HindIII sites downstream of the firefly luciferase coding
region of the pGL3 vector (Promega), resulting in pGL3-
Twist 3′UTR. Primer sequences are in Table 1. Mutation
from GTA to CAT was introduced in the potential miR-
300 binding sites (named pGL3-Twist 3′UTR-mut) by
using the QuickChange Stratagene method. The cor-
rect orientation of the insert was verified by sequen-
cing. 4 × 104 293 T cells were cultured in 24-well plates
and cotransfected with 0.15 μg of either pGL3-Twist 3′
UTR or pGL3-Twist 3′UTR-mut together with 0.05 μg of
the control vector containing renilla luciferase, pRL-TK
(Promega) and 40 pmol of miR-300 mimics. Transfection
was done using Lipofectamine 2000. Twenty-four hours
after transfection, firefly and renilla luciferase activity were
measured using the Dual-Luciferase Reporter Assay
(Promega) and firefly luciferase activity was normalized
to renilla luciferase activity. Each transfection was repeated
twice in triplicate. To assess the effect of the endogenous
miR-300, luciferase activities were also measured in HN-4
and MCF-7 cells in the presence of miR-300 inhibitor.
Rescue experiment
To further validate direct targeting of Twist by miR-300,
functional rescue experiment was performed by co-
transfection with miR-300 mimic and plasmid constructs
expressing Twist in HN-12 cells and MDA-MB-231
cells using Lipofectamine 2000 as described above. The
expression plasmid pcDNA-Twist, encoding human
Twist was purchased from Genechem. The presence ofcomplete Twist coding regions was confirmed by DNA
sequencing.
Experimental metastasis
All animal studies were conducted in accordance with
an Institutional Animal Care and Use Committee-
approved protocol at the Shanghai Jiao Tong University.
5-week-old female nude BALB/c mice were used in the
study. MDA-MB-231 cells stably transfected with miR-
300 or with negative control vector (2 × 106 cells in
0.2 ml PBS) were injected into mice via the tail vein.
Each treatment group consisted of 7 mice. After 6 weeks,
the mice were necropsied, and the lungs were removed.
Visible lung metastases were counted in Bouin’s fixed
tissues with the aid of a dissecting microscope [34].
Clinical sample
A total of seventy-five FFPE tissue specimens were ob-
tained from patients who were diagnosed with oral squa-
mous cell carcinoma (OSCC) and underwent surgical
resection between 2006 and 2007 in the Department of
Oral Pathology, Ninth People’s Hospital, Shanghai Jiao
Tong University School of Medicine, with (n = 35) or
without metastasis (n = 40). Real-time PCR analysis for
miR-300 and Twist mRNA was performed as described
above. Primer sequences are in Table 1. Correlation ana-
lysis between miR-300 level and Twist mRNA expression
was performed. The median value was used as cutoff point
for separating miR-300 high and low expression cases.
Statistical analysis
All data are presented as the mean value ± SD. Differences
between individual groups were analyzed by t-tests. P
values less than 0.05 (two-sided) were considered statisti-
cally significant. In order to determine the correlation coef-
ficient (R) and the significance (P) between the expression
of miR-300 and Twist mRNA, the Pearson’s correlation al-
gorithm was applied. Statistical analyses were performed
using the SPSS 11.5 software (SPSS Inc).
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